Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 17Terminated 4Withdrawn 2Active not recruiting 2Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 4Thoracic 3Myeloid 2Genitourinary 2Dermatologic 2Plasma cell 1Gynecologic 1

Conditions

Recurrence 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Nivolumab 18Ipilimumab 16pembrolizumab 15Cyclophosphamide 13trametinib 9Radiotherapy 8dabrafenib 6Interleukin-2 6sargramostim 5fludarabine phosphate 5aldesleukin 5Vemurafenib 5Peripheral Blood Stem Cell Transplantation 5Fluorouracil 5130-nm albumin-bound paclitaxel 5fludarabine 4Radiosurgery 4Melphalan 4Celecoxib 4encorafenib 3durvalumab 3binimetinib 3avelumab 3Vorinostat 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Leucovorin 3Granulocyte-Macrophage Colony-Stimulating Factor 3Cytarabine 3Capecitabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Sirolimus × Dermatologic × Clear all
NCT01843998 2015-06-04

Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)

Medical College of Wisconsin

Phase 2 Withdrawn
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

NCT01851408 2015-04-15

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

National Cancer Institute (NCI)

Phase 2 Withdrawn
Dermatologic

Melanoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡